Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

BACKGROUND: Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known. 5T4 is a non-secreted membrane glycoprotein expressed on clear cell and papillary RCCs. A mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kaufman, Howard L, Taback, Bret, Sherman, William, Kim, Dae Won, Shingler, William H, Moroziewicz, Dorota, DeRaffele, Gail, Mitcham, Josephine, Carroll, Miles W, Harrop, Richard, Naylor, Stuart, Kim-Schulze, Seunghee
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2631474/
https://ncbi.nlm.nih.gov/pubmed/19128501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-7-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados